We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Taro Pharmaceutical Industries Ltd. said that it expects to report 2005 sales in a range of approximately $295 million to $305 million, and net income in a range of approximately $14.0 million to $16.0 million.
The U.S. FDA has granted final approval to Israel-based Teva Pharmaceutical's abbreviated new drug application (ANDA) to market its generic version of Merck's Proscar (finasteride) tablets in dosages of 5 mg.
Michigan-based QuatRx Pharmaceuticals has licensed a portfolio of 17-beta HSD Type 1 (hydroxysteroid dehydrogenase) inhibitors and related technologies from Solvay Pharmaceuticals, headquartered in Belgium.
French drugmaker sanofi-aventis has announced that the European Commission (EC) has granted marketing authorization for Acomplia (rimonabant 20 mg/day) in all 25 European member states.
Japan-based Toray Industries has concluded a licensing agreement with Acologix, a California-based biopharmaceutical company specializing in the field of osteo-renal diseases, for AC-200 (phosphatonin), a drug candidate being developed by Acologix.
Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of Genentech/Roche/Chugai's Herceptin (trastuzumab) will nearly triple, reaching $3.3 billion in 2015, following positive data from several Phase III clinical trials that show improved disease-free survival of breast cancer patients.
Research and Markets has announced the addition of the new report from Espicom Business Intelligence Ltd entitled "Switzerland Generics Market Intelligence Report" to their offering.
Cobalis Corp., a pharmaceutical development company focused on the treatment of allergy and other atopic conditions, announced today that its Patent No. 1128835, titled "Cyanocobalamin Treatment in Allergic Disease," has been published by the European Patent Office in the European Patent Bulletin 06/25.
Pharsight Corporation, a leading provider of software and strategic services for optimizing clinical drug development, announced today that CTC Laboratory Systems Corporation of Tokyo, Japan, will distribute to the Japanese market Pharsight Knowledgebase Server, PKS Reporter, PKS Validation Suite, and Pharsight Trial Simulator.